ASRS 2023: Monthly Pegcetacoplan Shows Greater Reduction in Geographic Atrophy Lesion Growth
Meta-analysis reveals 30.4 percent reduction in lesion growth with PEG versus avacincaptad pegol at month 12
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.